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Brief Communication
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Habib Skhiri3, Jamil Hachicha2
1Nuclear Medicine Department, Pasteur Institute of Tunis, Tunis, 2Nephrology Department, Hedi
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ABSTRACT. Post-kidney transplant erythrocytosis (PTE) is one of the hematological compli-
cations in the renal transplant patients. While its pathogenesis still remains to be elucidated
completely, a number of therapies are available for the management of PTE. The aim of this
prospective study was to investigate whether angiogenesis may be involved in the pathogenesis of
post-transplant erythrocytosis by comparing its level with those of different classes of
erythrocytosis [polycythemia vera (PV), idiopathic erythrocytosis and secondary erythrocytosis].
The angiogenic activity was evaluated by the assessment of the serum vascular endothelial
growth factor (VEGF) levels, as one of circulating angiogenic factor, using a standardized
enzyme-linked immunosorbent assay commercial kit in 13 PTE (2 F/11 M), in 75 untreated
erythrocytosis non-transplant patients and in 21 healthy subjects controls. The results indicated
that VEGF was overproduced in advanced and untreated PV patients and to a lesser degree in
idiopathic erythrocytosis thus confirming an increased angiogenic activity. However, there is no
evidence of increased angiogenesis in PTE and in secondary erythrocytosis. The absence of
angiogenesis in PTE and its presence in PV is another argument that the pathogenesis of these
two entities is different.
Introduction
Post-kidney transplant erythrocytosis (PTE)
is one of the hematological complications in
kidney transplant patients, and it is characterized
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by persistent hematocrit levels above 51%
after kidney transplantation.1 This complica-
tion is reported to develop in 10–20% of the
kidney recipients within eight to 24 months
after successful transplantation.2-6 While the
pathogenesis of PTE still remains to be eluci-
dated completely, a number of therapies are
available for its management.
The aim of this prospective study was to in-
vestigate whether angiogenesis was involved
in the pathogenesis of PTE by comparing its
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level with those of the different classes of
erythrocytosis [polycythemia vera (PV), idio-
pathic erythrocytosis and secondary erythro-
cytosis].
Patients and Methods
All patients of our study underwent red cell
mass and plasma volume measurement with a
standardized radionuclide method (51Cr-labeled
erythrocytes, 125I-labeled human serum albumin)
to confirm or exclude absolute erythrocytosis.
True PTE was defined as an RBC mass >125%
of the theoretical values allowed for sex,
weight and height with no evidence of PV or
secondary polycythemia due to reduced arte-
rial oxygen or kidney and hepatic tumors.
The study patients were divided into three
groups. The first group included 13 PTE pa-
tients (2 F/11 M, mean age 39.4 ± 11.6 years).
The second group comprised 75 absolute ery-
throcytosis non-transplant patients divided by a
standardized series of investigations [complete
blood count, bone marrow tests, serum ery-
thropoietin level, measurement of arterial oxy-
gen saturation (SaO) abdominal ultrasound
and JAK2 mutation assays] into a primary ery-
throctosis (PV) (23 M–22 F; mean age 59.3
±13.7 years), secon-dary erythrocytosis (14 M;
mean age 53.2 ± 13.0 years) and idiopathic
pure erythrocytosis (16 M; mean age 41.1 ±
15.1 years), which was a heterogeneous sub-
group where the cause could not be esta-
blished. Finally, the third group comprised 21
healthy control individuals (normal RCM) (21
M; mean age 45.5 ± 14.7 years).
The angiogenic activity was evaluated by the
assessment of the serum levels of vascular
endothelial growth factor (VEGF), a circu-
lating angiogenic factor. An enzyme-linked
immuno-sorbent assay (ELISA) using a stan-
dardized commercial kit (Quantikine; R&D
Systems, Minneapolis, MN, USA) was used to
measure the VEGF levels.
Results
The average serum level of VEGF was 278 ±
121 pg/mL in the control group, demons-
trating a progressive rise to 634 ± 271 pg/mL
in the idiopathic erythrocytosis patients and
2233 ± 1861 pg/mL in the PV patients, while it
was not increased in the secondary erythro-
cytosis patients (350 ± 174 pg/mL) and in the
PTE patients (378 ± 181 pg/mL) compared
with that in the control group (Figure 1).
Discussion
Our results indicated that serum VEGF was
overproduced in advanced and untreated PV
patients and, to a lesser degree, in idiopathic
Figure 1. Level of serum vascular endothelial growth factor (VEGF) in the different groups of
erythrocytosis.
PTE: Post-transplant erythrocytosis, PV: Polycythemia vera.
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erythrocytosis thus confirming an increased
angiogenic activity. However, there was no
evidence of increased angiogenesis in PTE and
in secondary erythrocytosis.
 In our study, we studied only true erythro-
cytosis cases by measuring the RBC mass.
PTE remains an enigmatic syndrome unique to
renal transplant recipients. Predisposing fac-
tors include male gender,7 retention of native
kidneys, cyclosporine use4 and a rejection-free
course with a well-functioning renal graft.2,7,8
Its etiology is incompletely understood, and
the most frequently suggested causative fac-
tors are still a matter of controversy. It was
suggested that PTE results from the combined
trophic effect of multiple and interrelated
erythropoietic factors, inappropriately exces-
sive production of erythropoietin either by the
native or transplanted kidneys, enhanced sensi-
tivity of erythroid stem cells to erythropoietin
or altered regulation of the hematocrit-EPO
feedback system. Increased production of ery-
thropoietin may be caused by ischemia in the
renal artery and/or use of cyclosporine. How-
ever, erythropoietin levels in most PTE pa-
tients are within the normal range. Erythro-
cytosis may ensue the contributory action of
additional growth factors on erythroid proge-
nitors, such as angiotensin II,9 androgens7 and
insulin-like growth factor 1 (IGF-1).10-15 The
role of the oligopeptide N-acetyl-seryl-aspartyl-
lysyl-proline (Ac-SDKP), a natural inhibitor of
the pluripotent stem cell in the hematocrit-lo-
wering effect of angiotensin-converting enzyme
inhibition, in the development of PTE is still
controversial.1 Increased serum-soluble stem
cell factor (sSCF) levels seem to have a role in
the pathogenesis of PTE.16
The evaluation of angiogenesis may add
some important pathophysiological and prog-
nostic information of some diseases and may,
with clinical–therapeutic implication, that anti-
angiogenic agent may be a useful therapy of
angiogenesis-dependent diseases. Several studies
have shown that angiogenesis is an event in
myeloproliferative diseases and reported a
significant elevation in the serum levels of the
VEGF, which is the fundamental regulator of
differentiation of the hemangioblast (common
precursor for endothelial and hematopoitic
cells) in PV. We have confirmed and discussed
this in a previous study.17
In the present study, despite the fact that the
number of transplanted patients examined was
small, we have demonstrated that this VEGF
does not play an angiogenic role in PTE. The
absence of angiogenesis in PTE and its pre-
sence in PV is another argument that the
pathogenesis of these two entities is different.
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